Apple's Contempt Case in Epic Games Lawsuit Heads to Supreme Court
Money

Apple's Contempt Case in Epic Games Lawsuit Heads to Supreme Court

authorBy Scott Pape
DateJun 30, 2026
Read Time2 min
The U.S. Supreme Court will weigh in on the long-running legal dispute between tech giant Apple and game developer Epic Games, focusing on whether Apple violated a judicial order regarding its App Store payment policies. This high-stakes case has significant implications for the future of app distribution and digital commerce.

A Landmark Decision: Supreme Court to Address Apple's App Store Policies

Supreme Court Considers Apple's Appeal in Epic Games Dispute

The United States' highest court has granted a review of Apple's request to challenge a contempt ruling in its ongoing legal confrontation with Epic Games. This development stems from a judicial order requiring Apple to modify its App Store practices following a successful antitrust challenge by the creator of "Fortnite."

Background of the Apple-Epic Legal Battle

The contention between Apple and Epic Games originated from a 2020 lawsuit filed by Epic, which contested Apple's stringent control over transactions within applications operating on its iOS platform. A key point of contention was Apple's limitations on how applications could be distributed to consumers, particularly its 30% commission on in-app purchases.

The Genesis of the Contempt Finding

While Apple largely prevailed in Epic's initial lawsuit, a 2021 injunction mandated that the company permit developers to integrate links within their apps, directing users to alternative payment methods outside of Apple's ecosystem. Following this, Apple introduced new restrictions, including a 27% commission on purchases made via these external payment systems within seven days of a user clicking such a link. Epic argued that this new commission structure circumvented the spirit of the original injunction, leading to a civil contempt finding against Apple in 2025.

Appeals Court Upholds Contempt, Opens Door for Further Arguments

In December, the 9th U.S. Circuit Court of Appeals in San Francisco affirmed the contempt ruling against Apple. However, the appellate court also allowed Apple to present new arguments concerning the appropriate commission rate for digital goods purchased through third-party payment systems linked within App Store-distributed applications. These new proceedings are yet to commence at the district court level.

Apple's Defense and Global Implications

Apple maintains its compliance with the judge's original order, contending that the injunction should not extend beyond Epic Games to encompass millions of other developers. The company has emphasized to the Supreme Court that regulators worldwide are closely observing this case, as its outcome could influence the commission rates Apple is permitted to charge on covered purchases in major international markets. This case underscores the complex legal landscape surrounding digital marketplaces and their impact on global commerce.

More Articles
Money
Prologis Intensifies Acquisition Bid for Segro After Initial Rejection
Prologis is continuing its pursuit of Segro, a London-based logistics warehouse operator, following Segro's rejection of a £12.6 billion ($16.6 billion) takeover offer. Prologis has since provided a detailed explanation of its financial and strategic reasons for the merger, emphasizing the benefits to Segro's shareholders, including a 25% premium and access to Prologis' extensive network and strong balance sheet.
By JL CollinsJun 30, 2026
Money
Caris Life Sciences Expands Market Presence with Dual Listing and AI-Driven Precision Medicine Focus
Caris Life Sciences, Inc. (CAI) has announced a dual listing on NYSE Texas, effective June 17, 2026, while maintaining its Nasdaq presence. This strategic move aims to boost visibility among investors, especially within Texas, where the company's headquarters are located. Caris Life Sciences, a leader in TechBio and precision medicine, leverages molecular profiling and AI to enhance personalized oncology and chronic disease care. This expansion reinforces its commitment to innovative healthcare solutions and patient outcome improvement.
By T. Harv EkerJun 30, 2026
Money
Amylyx Pharmaceuticals: Breakthrough Potential in Neurodegenerative Treatment
Amylyx Pharmaceuticals (AMLX) is gaining significant attention from analysts, with Guggenheim recently increasing its price target to $40 and reiterating a Buy rating. This positive outlook is driven by the upcoming Phase 3 LUCIDITY trial results for avexitide, a treatment for post-bariatric hypoglycemia, expected in Q3. Additionally, early Phase 1 LUMINA trial data for AMX0114 in ALS showed promising safety, supporting further dose escalation. As a clinical-stage biopharmaceutical company, Amylyx focuses on innovative therapies for severe neurological conditions with high unmet medical needs.
By T. Harv EkerJun 30, 2026
Money
Ascentage Pharma Emerges as Key Player in Oncology Drug Development
Ascentage Pharma Group Internat (AAPG) is gaining significant attention for its innovative cancer therapies, with analysts initiating strong coverage. The company recently presented promising clinical updates on olverembatinib and lisaftoclax at EHA2026, showcasing sustained activity in various hematologic malignancies. These developments underscore AAPG's commitment to advancing cancer treatment and solidifying its position in the biotechnology sector.
By Bola SokunbiJun 30, 2026
Money
Nurix Therapeutics Inc. (NRIX) Price Target Boosted to $33 Due to Roche Collaboration Value
Nurix Therapeutics (NRIX) recently saw its price target increased to $33 by Baird, maintaining an Outperform rating. This adjustment reflects the significant value of its partnership with Roche and the ongoing progress of its clinical programs. Additionally, the company announced positive Phase 1a/b clinical trial results for bexobrutideg (NX-5948) in chronic lymphocytic leukemia (CLL) patients, showing strong response rates and a favorable safety profile, reinforcing the drug's potential for further development.
By T. Harv EkerJun 30, 2026